Abhishek Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abhishek Sharma has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Alan McNeill
Department of Urology Western General Hospital Edinburgh UK
2 shared publicationsClare Verrill
Nuffield Department of Surgical Sciences University of Oxford Oxford UK
2 shared publicationsDaniel W. Good
Department of Urology NHS Lothian, Western General Hospital Edinburgh UK
2 shared publicationsFergus Gleeson
Department of Radiology Oxford University Hospitals NHS Foundation Trust, Churchill Hospital Oxford UK
2 shared publicationsFreddie C. Hamdy
Department of Urology, Churchill Hospital Oxford University Hospitals NHS Foundation Trust Oxford UK
2 shared publicationsPhilip Camilleri
Department of Oncology, Churchill Hospital Oxford University Hospitals NHS Foundation Trust Oxford UK
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1013-1024
The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer
Objectives: Primary objective: to determine whether prostate gland partial ablation (PA) has non‐inferior oncological treatment success vs radical treatment (RT) of localised intermediate‐risk prostate cancer (irPCa). Secondary objectives: to compare (i) participant‐reported urinary and sexual dysfunction side effects, (ii) short/medium term serious adverse events, (iii) health‐related quality of life (HRQoL), (iv) cost‐effectiveness; and to report (v) the need for repeat PA, (vi) accuracy of magnetic resonance imaging and biopsy protocols in determining suitability for PA, (vii) disease progression, local spread and metastases, (viii) medium‐term disease‐specific and overall mortality. Participants and Methods: The ‘Partial prostate Ablation versus Radical Treatment’ (PART; International Standard Randomised Controlled Trial Number ISRCTN17249875) is a UK‐wide, multicentre, pragmatic, randomised controlled trial investigating whether PA (high‐intensity focused ultrasound [HIFU] or irreversible electroporation [IRE]) is non‐inferior to RT (radical prostatectomy, radical radiotherapy, or low‐dose‐rate brachytherapy [LDR‐B]) in treating localised irPCa. A Qualitative Research Integrated within Trials (QuinteT) Recruitment Intervention is included to optimise recruitment and informed consent. Primary outcome treatment success for PA will be determined by prostate biopsies and imaging, and for RT using standard definitions. Participants will receive treatment according to their randomised allocation, with HIFU or IRE for PA depending on lesion location, and radical prostatectomy, radical radiotherapy, or LDR‐B according to patient and physician preference for RT. Based on 95% and 85% oncological treatment success for RT and PA, respectively, with a non‐inferiority margin of 20%, at median 3 years of follow‐up, PART requires 275 recruited men (137 per group, randomised on a 1:1 basis), for 80% power, with a one‐sided alpha of 0.025. Allowing for a 10% total withdrawal or dropout rate, PART requires 306 recruited and randomised participants. Conclusions: The PART trial will provide robust prospective data and high‐level randomised evidence to determine oncological treatment effectiveness of PA vs RT for localised irPCa, along with comparative side effect, HRQoL, and health economics evaluations, to inform clinical decision‐making.
- 18 September 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1013-1024
Open AccessThe PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer
Objectives: Primary objective: to determine whether prostate gland partial ablation (PA) has non‐inferior oncological treatment success vs radical treatment (RT) of localised intermediate‐risk prostate cancer (irPCa). Secondary objectives: to compare (i) participant‐reported urinary and sexual dysfunction side effects, (ii) short/medium term serious adverse events, (iii) health‐related quality of life (HRQoL), (iv) cost‐effectiveness; and to report (v) the need for repeat PA, (vi) accuracy of magnetic resonance imaging and biopsy protocols in determining suitability for PA, (vii) disease progression, local spread and metastases, (viii) medium‐term disease‐specific and overall mortality. Participants and Methods: The ‘Partial prostate Ablation versus Radical Treatment’ (PART; International Standard Randomised Controlled Trial Number ISRCTN17249875) is a UK‐wide, multicentre, pragmatic, randomised controlled trial investigating whether PA (high‐intensity focused ultrasound [HIFU] or irreversible electroporation [IRE]) is non‐inferior to RT (radical prostatectomy, radical radiotherapy, or low‐dose‐rate brachytherapy [LDR‐B]) in treating localised irPCa. A Qualitative Research Integrated within Trials (QuinteT) Recruitment Intervention is included to optimise recruitment and informed consent. Primary outcome treatment success for PA will be determined by prostate biopsies and imaging, and for RT using standard definitions. Participants will receive treatment according to their randomised allocation, with HIFU or IRE for PA depending on lesion location, and radical prostatectomy, radical radiotherapy, or LDR‐B according to patient and physician preference for RT. Based on 95% and 85% oncological treatment success for RT and PA, respectively, with a non‐inferiority margin of 20%, at median 3 years of follow‐up, PART requires 275 recruited men (137 per group, randomised on a 1:1 basis), for 80% power, with a one‐sided alpha of 0.025. Allowing for a 10% total withdrawal or dropout rate, PART requires 306 recruited and randomised participants. Conclusions: The PART trial will provide robust prospective data and high‐level randomised evidence to determine oncological treatment effectiveness of PA vs RT for localised irPCa, along with comparative side effect, HRQoL, and health economics evaluations, to inform clinical decision‐making.
- 31 March 2026
- Published by Wiley in BJU International
- Vol. 137 (6) , 1097-1098
Reconciling primary outcomes and statistical power: comment on a randomised controlled trial on prostate biopsy approaches
- 31 March 2026
- Published by Wiley in BJU International
- Vol. 137 (6) , 1097-1098
Reconciling primary outcomes and statistical power: comment on a randomised controlled trial on prostate biopsy approaches
- Open Access
- 26 February 2026
- Published by Wiley in BJU International
- Vol. 137 (5) , 849-857
The PRAGMATIC pathway ‐ PRostate cancer diAGnosis and MAnagement Triage In Clinical care
Objectives: To investigate whether nurse navigator‐led triaging of high‐risk patients may reduce prostate cancer (PCa) diagnosis and treatment times using an in‐house bespoke PRostate cancer diAGnosis and MAnagement Triage In the Clinial care pathway (PRAGMATIC) triaging system, as locally advanced/metastatic disease should be diagnosed and treated rapidly, and UK targets allow 28 days for diagnosis, and 62 days to commence treatment. Patients and Methods: We reviewed diagnosis and treatment timelines for patients undergoing 28/62‐day investigation for suspected PCa at a tertiary unit in a 3‐month period (2022). We then introduced nurse navigator‐led triaging of urgent referrals and evaluated a subsequent 3‐month period (2024), with streamlining for rapid investigation and treatment based on prostate‐specific antigen, magnetic resonance imaging (MRI) staging, and histology. We hypothesised nurse navigator‐led triaging would improve investigation and treatment times for high‐risk localised, or locally advanced, or metastatic PCa. Results: A total of 165 and 327 consecutive patients were on the 28/62‐day PCa pathway in the pre‐ (2022) and post‐nurse navigator‐led (2024) triaging periods, respectively. The median time from referral to first appointment (8 vs 4 days), MRI (12 vs 6 days), MRI result (26 vs 17 days), biopsy decision (25 vs 16 days), biopsy procedure (48 vs 22 days), biopsy result communication (64 vs 44 fays), and prostate‐specific membrane antigen positron emission tomography computed tomography staging scan (87 vs 56 days) was reduced following nurse navigator triaging of high‐risk cases (all P < 0.001). The median time from referral to treatment for Gleason Grade Group ≥3, or T3, or ≥N1, or ≥M1 disease (104 vs 70 days; 49/75 [65.3%] vs 72/128 [56.3%] patients), and for M1b disease (47 vs 27 days; 15/75 [20%] vs 32/128 [25%] patients), was reduced ( P < 0.05). Conclusions: Nurse navigator‐led triaging and stratification of the most clinically urgent suspected PCa cases was associated with improved imaging, biopsy diagnosis, and treatment times for the highest‐risk patients.
- 26 February 2026
- Published by Wiley in BJU International
- Vol. 137 (5) , 849-857
Open AccessThe PRAGMATIC pathway ‐ PRostate cancer diAGnosis and MAnagement Triage In Clinical care
Objectives: To investigate whether nurse navigator‐led triaging of high‐risk patients may reduce prostate cancer (PCa) diagnosis and treatment times using an in‐house bespoke PRostate cancer diAGnosis and MAnagement Triage In the Clinial care pathway (PRAGMATIC) triaging system, as locally advanced/metastatic disease should be diagnosed and treated rapidly, and UK targets allow 28 days for diagnosis, and 62 days to commence treatment. Patients and Methods: We reviewed diagnosis and treatment timelines for patients undergoing 28/62‐day investigation for suspected PCa at a tertiary unit in a 3‐month period (2022). We then introduced nurse navigator‐led triaging of urgent referrals and evaluated a subsequent 3‐month period (2024), with streamlining for rapid investigation and treatment based on prostate‐specific antigen, magnetic resonance imaging (MRI) staging, and histology. We hypothesised nurse navigator‐led triaging would improve investigation and treatment times for high‐risk localised, or locally advanced, or metastatic PCa. Results: A total of 165 and 327 consecutive patients were on the 28/62‐day PCa pathway in the pre‐ (2022) and post‐nurse navigator‐led (2024) triaging periods, respectively. The median time from referral to first appointment (8 vs 4 days), MRI (12 vs 6 days), MRI result (26 vs 17 days), biopsy decision (25 vs 16 days), biopsy procedure (48 vs 22 days), biopsy result communication (64 vs 44 fays), and prostate‐specific membrane antigen positron emission tomography computed tomography staging scan (87 vs 56 days) was reduced following nurse navigator triaging of high‐risk cases (all P < 0.001). The median time from referral to treatment for Gleason Grade Group ≥3, or T3, or ≥N1, or ≥M1 disease (104 vs 70 days; 49/75 [65.3%] vs 72/128 [56.3%] patients), and for M1b disease (47 vs 27 days; 15/75 [20%] vs 32/128 [25%] patients), was reduced ( P < 0.05). Conclusions: Nurse navigator‐led triaging and stratification of the most clinically urgent suspected PCa cases was associated with improved imaging, biopsy diagnosis, and treatment times for the highest‐risk patients.
- Open Access
- 2 July 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (7)
The impact of haemostatic agent used during robot‐assisted radical prostatectomy on post‐op infection and anastomotic leak
Objective: Despite the widespread use of robotic‐assisted radical prostatectomy (RARP), considerable variation exists in practice with regard to postoperative cystograms prior to trial without catheter (TWOC).Our practice was to undertake a cystogram at 7–14‐day post‐op and proceed with TWOC if the leak was small or absent.In this study, we evaluate the risk factors for anastomotic leak and post‐op urinary tract infection (UTI), while assessing the impact of using powdered haemostat Arista AH on post‐op UTIs and cystographic leaks to rationalise the use of cystograms.Methods: The study was carried out in two phases, the first a retrospective review of 154 patients undergoing RARP between January and October 2022, where Oxitamp (an absorbable haemostat of oxidised regenerated cellulose) was used as the haemostatic agent.The second phase was prospective, involving 62 patients between November and June 2023, in whom the powdered haemostat Arista AH (microporous polysaccharide haemospheres) was used instead.Data were collated from a prospectively collected database (REDCapÒ) and electronic patient records. RARP was performed by two experienced surgeons using similar techniques. Analysis was carried out on R‐studios, using Fisher's exact test for categorical variables and unpaired student t‐test for continuous variables.Results: Post‐op UTI occurred in 19 (12%) patients in Cohort 1 (with Oxitamp) and leaks were associated with 15 (79%). In comparison, seven (11%) patients in Cohort 2 (with Arista AH) suffered from post‐op UTI, and only one (14%) was associated with leak.There was an overall reduction in leaks on post‐op cystograms from 44 (29%) in Cohort 1 to only nine (15%) in Cohort 2 (p = 0.036).One hundred per cent of the leaks in Cohort 2 were small, compared to nine (20%) in Cohort 1 (p = 0.0002).Conclusions: A selective approach can be implemented with regard to post‐op cystograms.We propose that when using Arista AH cystograms should be carried out in patients in need of bladder neck reconstruction. We will also continue to undertake routine cystograms in those with a history of transurethral resection of prostate (TURP) or in salvage prostatectomy cases.
- 2 July 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (7)
Open AccessThe impact of haemostatic agent used during robot‐assisted radical prostatectomy on post‐op infection and anastomotic leak
Objective: Despite the widespread use of robotic‐assisted radical prostatectomy (RARP), considerable variation exists in practice with regard to postoperative cystograms prior to trial without catheter (TWOC).Our practice was to undertake a cystogram at 7–14‐day post‐op and proceed with TWOC if the leak was small or absent.In this study, we evaluate the risk factors for anastomotic leak and post‐op urinary tract infection (UTI), while assessing the impact of using powdered haemostat Arista AH on post‐op UTIs and cystographic leaks to rationalise the use of cystograms.Methods: The study was carried out in two phases, the first a retrospective review of 154 patients undergoing RARP between January and October 2022, where Oxitamp (an absorbable haemostat of oxidised regenerated cellulose) was used as the haemostatic agent.The second phase was prospective, involving 62 patients between November and June 2023, in whom the powdered haemostat Arista AH (microporous polysaccharide haemospheres) was used instead.Data were collated from a prospectively collected database (REDCapÒ) and electronic patient records. RARP was performed by two experienced surgeons using similar techniques. Analysis was carried out on R‐studios, using Fisher's exact test for categorical variables and unpaired student t‐test for continuous variables.Results: Post‐op UTI occurred in 19 (12%) patients in Cohort 1 (with Oxitamp) and leaks were associated with 15 (79%). In comparison, seven (11%) patients in Cohort 2 (with Arista AH) suffered from post‐op UTI, and only one (14%) was associated with leak.There was an overall reduction in leaks on post‐op cystograms from 44 (29%) in Cohort 1 to only nine (15%) in Cohort 2 (p = 0.036).One hundred per cent of the leaks in Cohort 2 were small, compared to nine (20%) in Cohort 1 (p = 0.0002).Conclusions: A selective approach can be implemented with regard to post‐op cystograms.We propose that when using Arista AH cystograms should be carried out in patients in need of bladder neck reconstruction. We will also continue to undertake routine cystograms in those with a history of transurethral resection of prostate (TURP) or in salvage prostatectomy cases.
- 19 October 2023
- Published by Elsevier in European Urology
- Vol. 85 (2) , 179
Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment
- 19 October 2023
- Published by Elsevier in European Urology
- Vol. 85 (2) , 179
Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment